Drug–drug interactions (DDIs) are one of the most frequent causes of adverse drug
reactions or loss of treatment efficacy. The risk of DDIs increases with polypharmacy and is …

Abstract Background and Objective Although the separate effects of drug–drug interactions
and pregnancy on antiretroviral drug pharmacokinetics have been widely studied and …

Substantial anatomical and physiological changes occur during pregnancy and labor, which
impact on drug absorption, distribution, metabolism, and elimination. Reduced maternal …

Background: The choice of malaria treatment for HIV-infected pregnant women receiving
efavirenz-based antiretroviral therapy must consider the potential impact of drug interactions …

Abstract Background and Objective Advances in antiretroviral therapy led to an increase in
life expectancy among people living with human immunodeficiency virus (HIV). As aging is …

Introduction The association between pregnancy and altered drug pharmacokinetic (PK)
properties is acknowledged, as is its impact on drug plasma concentrations and thus …

Background As per current treatment guidelines, artemether-lumefantrine and efavirenz-
based antiretroviral therapy are recommended drugs for falciparum malaria and human …

Aim: We aimed to assess the effect of a functional polymorphism of CYP3A5 on lumefantrine
pharmacokinetics. Patients & methods: Sixty-nine women diagnosed with malaria received …

Introduction Mother-to-child transmission (MTCT) of HIV is thought to account for over 90%
of new pediatric infections, and is associated with poor maternal and fetal outcomes. As …

Malaria and HIV co‐infection are prevalent in sub‐Saharan Africa causing significant drug
interactions with co‐treatment. We previously reported a 30%‐70% reduction in exposure to …